Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Longyun Peng has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiometabolic multimorbidity and mortality in calcific aortic valve stenosis: the ARISTOTLE cohort study

    by Jiayuan Zhang, Ziwei Zhou, Xinghao Xu, Yue Guo, Zhenyu Xiong, Menghui Liu, Shaozhao Zhang, Rihua Huang, Han Wen, Yiqi Zheng, et al.

    Background: Cardiometabolic multimorbidity (CMM), defined as the coexistence of two or more cardiometabolic diseases (CMDs), is highly prevalent in patients with calcific aortic valve stenosis (CAVS). However, its association with mortality in this population remains poorly characterized. Methods: This retrospective cohort study analyzed 1175 adults with echocardiographically confirmed CAVS from the ARISTOTLE (Aortic valve diseases RISk facTOr assessmenT and prognosis modeL construction) registry. Participants were stratified by baseline CMD count into pre-specified primary exposure groups: CMM0 (no CMD), CMM1 (one CMD), and CMM2–3 (≥ 2 CMDs). CMDs included type 2 diabetes mellitus (T2DM), coronary heart disease (CHD), and ischemic stroke. Cause-specific Cox proportional-hazards models were applied; non-cardiovascular deaths were treated as censoring events for cardiovascular mortality analyses. Fine–Gray competing-risk models were constructed, with non-cardiovascular death set as the competing event. Formal interaction testing with Bonferroni correction was conducted for pre-defined subgroup analyses. Exploratory four-category CMD stratification and analyses of distinct CMD combinations were presented in supplementary materials. Results: During a median follow-up of 3.23 years, 329 all-cause deaths and 179 cardiovascular deaths occurred. Mortality risk tended to increase with higher cardiometabolic multimorbidity burden. In the fully adjusted model, participants with ≥ 2 CMDs showed higher risk of all-cause mortality (HR 1.74, 95% CI 1.23–2.48; P = 0.002) and cardiovascular mortality (HR 2.24, 95% CI 1.39–3.61; P < 0.001), compared with patients without CMD. Each incremental rise in CMD count was associated with 30% higher all-cause death risk (HR 1.30, 95% CI 1.10–1.53, P = 0.002) and 47% higher cardiovascular death risk (HR 1.47, 95% CI 1.18–1.84, P < 0.001). Fine–Gray competing-risk analyses yielded consistent findings (subdistribution HR 2.07, 95% CI 1.30–3.28, P = 0.002 for CMM2–3 versus CMM0). Associations between CMD burden and mortality were directionally uniform across most predefined subgroups; no statistically significant interaction remained after Bonferroni correction for multiple comparisons. Conclusions: Among patients with calcific aortic valve stenosis, higher cumulative cardiometabolic multimorbidity burden was independently associated with elevated all‑cause and cardiovascular mortality. These observational findings suggest that assessment of cumulative cardiometabolic comorbidity burden may add prognostic context for patients with CAVS.

  • Open Access

    The Association Between Inflammatory Indices and Mortality in Patients with Moderate-to-Severe Tricuspid Regurgitation

    by Jiayuan Zhang, Mengjie Xie, Ziwei Zhou, Xinghao Xu, Yue Guo, Zhenyu Xiong, Min Ye, Rui Fan, Menghui Liu, Han Wen, et al.

    Background Tricuspid regurgitation (TR) is a common valvular lesion associated with high mortality, yet readily accessible prognostic biomarkers remain scarce. We aimed to evaluate the associations of the systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) with long-term mortality in patients with moderate-to-severe TR. Methods In this retrospective cohort (TRAIL study, NCT06926959 ), 1,349 patients with moderate-to-severe TR were followed for a median of 4.9 years. Multivariable Cox regression and restricted cubic spline analyses assessed the associations between log-transformed SII/NLR and all-cause mortality. Missing covariates were handled by multiple imputation. Results During follow-up, 523 deaths (39%) occurred. Each one-unit increase in log-transformed SII (LnSII) and NLR (LnNLR) was associated with a 26% (Hazard Ratio (HR)=1.26, 95% Confidence Interval (CI)=1.14?1.41) and 57% (HR=1.57, 95% CI: 1.39-1.77) increased risk of all-cause mortality, respectively. Compared to the lowest quartile, the highest quartile conferred a 45% increased risk for SII (HR=1.45, 95% CI: 1.13-1.85) and a 126% increased risk for NLR (HR=2.26, 95% CI: 1.72-2.97). Restricted cubic splines revealed non-linear relationships (P-nonlinearity=0.009 for SII; P=0.016 for NLR) with inflection points at LnSII=5.553 and LnNLR=0.466. The association of NLR was stronger in non-hypertensive patients (P-interaction=0.006), while SII remained consistent across subgroups. Conclusions Elevated SII and NLR are independently associated with increased all-cause mortality in moderate-to-severe TR, with NLR exhibiting enhanced predictive value in non-hypertensive individuals. These inexpensive indices may improve risk stratification and guide management.

  • Open Access

    Incidence of chemotherapy‐related cardiac dysfunction in cancer patients

    by Hai‐Wei Deng, Rui Fan, Yuan‐Sheng Zhai, Jie Li, Zhi‐Bin Huang, Long‐Yun Peng

    Background: Cancer patients are increasingly affected by chemotherapy‐related cardiac dysfunction. The reported incidence of this condition vary significantly across different studies.Hypothesis: A better comprehensive understanding of chemotherapy‐related cardiac dysfunction incidence in cancer patients is imperative. Therefore, we performed a meta‐analysis to establish the overall incidence of chemotherapy‐related cardiac dysfunction in cancer patients.Methods: We searched articles in PubMed and EMBASE from database inception to May 1, 2023. Studies that reported the incidence of chemotherapy‐related cardiac dysfunction in cancer patients were included.Results: A total of 53 studies involving 35 651 individuals were finally included in the meta‐analysis. The overall pooled incidence of chemotherapy‐related cardiac dysfunction in cancer patients was 63.21 per 1000 person‐years (95% CI: 57.28−69.14). The chemotherapy‐related cardiac dysfunction incidence increased steeply within half a year of cancer chemotherapy. Also, the trend of chemotherapy‐related cardiac dysfunction incidence appeared to have plateaued after a longer duration of follow‐up. In addition, chemotherapy‐related cardiac dysfunction incidence rates are significantly higher among patients with age ≥50 years versus patients with age <50 years (99.96 vs. 34.48 per 1000 person‐years). The incidence rate of cardiac dysfunction was higher among breast cancer patients (72.97 per 1000 person‐years), leukemia patients (65.21 per 1000 person‐years), and lymphoma patients (55.43 per 1000 person‐years).Conclusion: Our meta‐analysis unveiled a definitive overall incidence rate of chemotherapy‐related cardiac dysfunction in cancer patients. In addition, it was found that the risk of developing this condition escalates within the initial 6 months postchemotherapy, subsequently tapering off to become statistically insignificant after a duration of 6 years.


  • Open Access

    Effect of Intensive Lifestyle Intervention on Cardiovascular Risk Factors: Analysis From the Perspective of Long‐Term Variability

    by Lixiang He, Menghui Liu, Xiaodong Zhuang, Yue Guo, Peng Wang, Zhuoming Zhou, Zhuohui Chen, Longyun Peng, Xinxue Liao

    Background: An association between variability of cardiovascular risk factors and cardiovascular events has been reported. We examined whether intensive lifestyle intervention (ILI) for weight loss decreased variability of cardiovascular risk factors with a view to additional cardiometabolic benefits. Methods and Results: This study was a post hoc secondary analysis of the Look AHEAD (Action for Health in Diabetes) study. Cardiovascular risk factors were measured at 1‐year intervals for 4 years in 4249 adults with overweight or obesity and type 2 diabetes who were randomly assigned to ILI or diabetes support and education. Long‐term variability was defined as the SD of cardiovascular risk factors during 4‐year follow‐up. At multiple linear regression analysis, compared with the diabetes support and education group, the ILI group was associated with reduced variability of fasting blood glucose (β=−1.49 [95% CI, −2.39 to −0.59]), total cholesterol (β=−1.12 [95% CI, −1.75 to −0.48]), and low‐density lipoprotein cholesterol (β=−1.04 [95% CI, −1.59 to −0.49]), as well as increased variability of systolic blood pressure (β=0.27 [95% CI, 0.00–0.54]). No significant effect of ILI was found on the variability of diastolic blood pressure (β=−0.08 [95% CI, −0.22 to 0.05]). Conclusions: Among adults with overweight or obesity and type 2 diabetes, ILI may reduce long‐term variability of fasting blood glucose, total cholesterol, and low‐density lipoprotein cholesterol. Our results support that ILI should be recommended to individuals with diabetes as part of management of long‐term glycemic and blood lipid control.


  • Open Access

    Plasma Fibronectin as a Novel Predictor of Coronary Heart Disease: A Retrospective Study

    by Longyun Peng, Haiwei Deng, Jie Li, Guihua Lu, Yuan-Sheng Zhai

    Although fibronectin has been associated with the pathogenesis of atherosclerosis, little is currently known about the relationship between plasma fibronectin and coronary heart disease (CHD). This retrospective study aimed to determine the predictive value of plasma fibronectin for CHD and its severity. A total of 1644 consecutive patients who underwent selective coronary angiography were recruited into the present study. The characteristics and results of the clinical examination of all patients were collected. Logistic regression analyses were performed to determine the predictive value of plasma fibronectin for the presence and severity of CHD. Compared with non-CHD patients, the CHD patients showed significantly higher plasma levels of troponin I and creatine kinase isoenzyme, along with lower plasma levels of fibronectin. However, no significant differences were detected in plasma fibronectin among patients with different grades of CHD. The logistic regression model showed that plasma fibronectin remained an independent predictor of CHD after adjustment with a 1.39-fold increased risk for every 1 SD decrease in plasma fibronectin. Nevertheless, plasma fibronectin could not predict the severity of CHD determined by the number of stenosed vessels and the modified Gensini score. This study demonstrated that lower plasma fibronectin might be an independent predictor of CHD, but it may be of no value in predicting the severity of CHD.


  • Open Access

    Associations of Renal Function Trajectories and Long‐Term Cardiovascular Risks Among a Population Without Chronic Kidney Disease

    by Yuan‐Sheng Zhai, Yun‐Jiu Cheng, Hai‐Wei Deng, Jie Li, Longyun Peng, Xiuren Gao

    Background: The longitudinal trajectories of renal function have been associated with cardiovascular events in patients with chronic kidney disease (CKD). However, the change pattern of renal function in those without CKD has not yet been reported. We aim to explore patterns of renal function change in a non‐CKD population and its associated risks with cardiovascular outcomes. Methods and Results: The present study analyzed data from 4 prospective cohorts and was restricted to participants without baseline CKD. The primary outcome was major adverse cardiovascular events, defined as a composite of myocardial infarction, chronic heart failure, stroke, and cardiovascular deaths. We used a group‐based trajectory model to identify latent groups and analyzed the associated risk with Cox regression models. The complete dates of this study were June 1, 2020, through January 1, 2021. The final sample comprised 23 760 participants (mean age, 58.63 [9.12] years, 10 618 men, and 17 799 White participants). During 20.56 years follow‐up, 8328 (35.05%) first major adverse cardiovascular events happened. Four trajectories in estimated glomerular renal function and 3 patterns of CKD progression were identified. Compared with subjects assigned to class I trajectory (high to mildly decreased group), the adjusted hazard ratios of major adverse cardiovascular events for class II (normal to mildly decreased group), class III (normal to moderately decreased group), and class IV (mildly to severely decreased group) were 1.11 (95% CI, 1.01–1.23), 1.27 (95% CI, 1.14–1.40), and 1.56 (95% CI, 1.38–1.77), respectively. Likewise, participants assigned to the slow and rapid progression groups had elevated HRs for major adverse cardiovascular events (1.75 [95% CI, 1.39–2.21] and 2.19 [95% CI, 1.68–2.86], respectively) when compared with the stable group. Findings were generally consistent in stratification analysis, but significant interaction effects by age and smoking status were detected. Conclusions: In this study, we identified unique trajectory groups for renal function. These findings may signal an underlying high‐risk population and inspire future studies on individualized risk management.


  • Association of metabolically healthy obesity in young adulthood with myocardial structure and function

    by Peng Wang, Menghui Liu, Xiaodong Zhuang, Yue Guo, Zhenyu Xiong, Lixiang He, Xiaojie Cai, Zhuohui Chen, Longyun Peng, Xinxue Liao

    Background Obesity is major cause of cardiovascular diseases. Metabolically healthy obesity (MHO) may increase heart failure risk early in life, and may be reflected in impaired cardiac structure and function. Therefore, we aimed to examine the relationship between MHO in young adulthood and cardiac structure and function. Methods A total of 3066 participants from the Coronary Artery Risk Development in Young Adults (CARDIA) study were included, who completed echocardiography in young adulthood and middle age. The participants were grouped by obesity status (body mass index ≥30 kg/m2) and poor metabolic health (≥2 criteria for metabolic syndrome) into four metabolic phenotypes as follows: metabolically healthy non-obesity (MHN), MHO, metabolically unhealthy non-obesity (MUN), metabolically unhealthy obesity (MUO). The associations of the metabolic phenotypes (MHN serving as the reference) with left ventricular (LV) structure and function were evaluated using multiple linear regression models. Results At baseline, mean age was 25 years, 56.4% were women, and 44.7% were black. After a follow-up 25 years, MUN in young adulthood was associated with worse LV diastolic function (E/é ratio, β [95% CI], 0.73 [0.18, 1.28]), worse systolic function (global longitudinal strain [GLS], 0.60 [0.08, 1.12]) in comparison with MHN. MHO and MUO were associated with LV hypertrophy (LV mass index, 7.49 g/m2 [4.63, 10.35]; 18.23 g/m2 [12.47, 23.99], respectively), worse diastolic function (E/é ratio, 0.67 [0.31, 1.02]; 1.47 [0.79, 2.14], respectively), and worse systolic function (GLS, 0.72 [0.38, 1.06]; 1.35 [0.64, 2.05], respectively) in comparison with MHN. These results were consistent in several sensitivity analyses. Conclusions In this community-based cohort using data from the CARDIA study, obesity in young adulthood was significantly associated with LV hypertrophy, worse systolic and diastolic function regardless of metabolic status. Relationship of Baseline Metabolic Phenotypes with Young Adulthood and Midlife Cardiac Structure and Function. Adjusted for year 0 covariates: age, sex, race, educational level, smoking status, drinking status, and physical activity; metabolically healthy non-obesity was used as a reference category for comparison. † Criteria for metabolic syndrome are listed in Supplementary Table S6. MUN metabolically unhealthy non-obesity, MHO metabolically healthy obesity, LVMi left ventricular mass index, LVEF left ventricular ejection fraction, E/A early to late peak diastolic mitral flow velocity ratio, E/é mitral inflow velocity to early diastolic mitral annular velocity, CI confidence interval.


  • Open Access

    Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction

    by Yuan-Sheng Zhai, Jie Li, Longyun Peng, Guihua Lu, Xiuren Gao

    Both aldosterone and arginine vasopressin (AVP) are produced in the heart and may participate in cardiac fibrosis. However, their relationship remains unknown. This study aims to demonstrate the regulation and role of AVP in aldosterone synthesis in the heart. Rats were subjected to a sham operation or myocardial infarction (MI) by ligating the coronary artery. Cardiac function and fibrosis were assessed using echocardiography and immunohistochemical staining, respectively. In addition, the effects of AVP stimulation on cardiac microvascular endothelial cells (CMECs) were studied using ELISA, real-time PCR, and Western blotting. Compared with the rats having undergone a sham operation, the MI rats had an increased LVMI, type I collagen composition, and concentrations of aldosterone and AVP in the heart but decreased cardiac function. As the MI rats aged, the LVMI, type I collagen, aldosterone, and AVP increased, while the LVMI decreased. Furthermore, AVP time-dependently induced aldosterone secretion and CYP11B2 mRNA expression in CMECs. The p-CREB levels were significantly increased by AVP. Nevertheless, these effects were completely blocked by SR49059 or partially inhibited by KN93. This study demonstrated that AVP could induce the secretion of local cardiac aldosterone, which may involve CaMK and CREB phosphorylation and CYP11B2 upregulation through V1 receptor activation.


  • Open Access

    Greater Adherence to Dietary Guidelines Associated with Reduced Risk of Cardiovascular Diseases in Chinese Patients with Type 2 Diabetes

    by Shang-Ling Wu, Long-Yun Peng, Yu-Ming Chen, Fang-Fang Zeng, Shu-Yu Zhuo, Yan-Bing Li, Wei Lu, Pei-Yan Chen, Yan-Bin Ye

    The evidence regarding the impact of the scores on healthy eating indices on the risk of cardiovascular events among patients with type 2 diabetes (T2D) is limited. As such, in this study, we examined the associations of adherence to the Chinese and American dietary guidelines and the risk of cardiovascular disease (CVD) among Chinese individuals with T2D. We conducted a 1:1 age- and sex-matched case–control study based on a Chinese population. We used a structured questionnaire and a validated 79-item food-frequency questionnaire to collect general information and dietary intake information, and calculated the Chinese Healthy Eating Index (CHEI) and the Healthy Eating Index-2015 (HEI-2015). As participants, we enrolled a total of 419 pairs of hospital-based CVD cases and controls, all of whom had T2D. We found a significant inverse association between diet quality scores on the CHEI and HEI-2015 and the risk of CVD. The adjusted odds ratios (95% confidence interval) per five-score increment were 0.68 (0.61, 0.76) in the CHEI and 0.60 (0.52, 0.70) in the HEI-2015. In stratified analyses, the protective associations remained significant in the subgroups of sex, BMI, smoking status, tea-drinking, hypertension state, dyslipidemia state, T2D duration, and medical nutrition therapy knowledge (all p < 0.05). These findings suggest that a higher CHEI or HEI-2015 score, representing a higher-quality diet relative to the most recent Chinese or American dietary guidelines, was associated with a decreased risk of CVD among Chinese patients with T2D.


  • Open Access

    Salvianolic Acid B Suppresses ER Stress‐Induced NLRP3 Inflammasome and Pyroptosis via the AMPK/FoxO4 and Syndecan‐4/Rac1 Signaling Pathways in Human Endothelial Progenitor Cells

    by Yubo Tang, Qingde Wa, Longyun Peng, Yifan Zheng, Jie Chen, Xiao Chen, Xuenong Zou, Huangxuan Shen, Shuai Huang

    Mounting evidence demonstrates uncontrolled endoplasmic reticulum (ER) stress responses can activate the inflammasome, which generally results in endothelial dysfunction, a major pathogenetic factor of chronic inflammatory diseases such as atherosclerosis. Salvianolic acid B (SalB), produced by Radix Salviae, exerts antioxidative and anti‐inflammatory activities in multiple cell types. However, SalB’s effects on ER stress‐related inflammasome and endothelial dysfunction remain unknown. Here, we showed SalB substantially abrogated ER stress‐induced cell death and reduction in capillary tube formation, with declined intracellular reactive oxygen species (ROS) amounts and restored mitochondrial membrane potential (MMP), as well as increased expression of HO‐1 and SOD2 in bone marrow‐derived endothelial progenitor cells (BM‐EPCs). ER stress suppression by CHOP or caspase‐4 siRNA transfection attenuated the protective effect of SalB. Additionally, SalB alleviated ER stress‐mediated pyroptotic cell death via the suppression of TXNIP/NLRP3 inflammasome, as evidenced by reduced cleavage of caspase‐1 and interleukin‐ (IL‐) 1β and IL‐18 secretion levels. Furthermore, this study provided a mechanistic basis that AMPK/FoxO4/KLF2 and Syndecan‐4/Rac1/ATF2 signaling pathway modulation by SalB substantially prevented BM‐EPCs damage associated with ER stress by decreasing intracellular ROS amounts and inducing NLRP3‐dependent pyroptosis. In summary, our findings identify that ER stress triggered mitochondrial ROS release and NLRP3 generation in BM‐EPCs, while SalB inhibits NLRP3 inflammasome‐mediated pyroptotic cell death by regulating the AMPK/FoxO4/KLF2 and Syndecan‐4/Rac1/ATF2 pathways. The current findings reveal SalB as a potential new candidate for the treatment of atherosclerotic heart disease.